Incyte Genomics INCY has been involved in a number of noteworthy events. First, they are set to present at both J.P. Morgan's 43rd Annual Healthcare Conference in January 2025 and at Citi's 2024 Global Healthcare Conference. However, they also paused enrollment in a Chronic Spontaneous Urticaria Study, and halted a key drug trial due to safety concerns. They are gearing up to report for Q3, although their Q2 earnings fell below estimates while their revenues exceeded. Stock options and RSUs have been awarded to 27 new hires in a strategic move and under their 2024 Inducement Plan. Their stock has experienced fluctuations, peaking at 2.1% and 0.9% increases following earnings reports. Incyte's late-stage NSCLC study fulfilled both primary and secondary objectives, and they were listed among the Top 5 Companies on Science Magazine’s 2024 Top Employers List. Survival benefit was demonstrated by their cancer drug in a Phase 3 Lung cancer trial and they announced promising new data at ESMO. However, INCY stock has plunged 29.6% YTD.
Incyte Genomics INCY News Analytics from Thu, 05 Mar 2015 08:00:00 GMT to Tue, 17 Dec 2024 08:00:00 GMT -
Rating 0
- Innovation -2
- Information 8
- Rumor -3
